Daniel DeAngelo on Muck Rack

Daniel DeAngelo

Tampa
As seen in: GameRant, MSN, Color Research & Application, MSN Malaysia, MSN South Africa, Nature, Wiley Online Library, Journal of Clinical Pathology, JAMA (The Journal of the American Medical Association), JAMA: Journal of the American Medical Association, The Lancet and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Daniel

Contact Daniel, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Insights from the ASCO Annual Meeting

|
By Daniel DeAngelo
| Oncology Learning Network
Clinical Summary: Design/Population: Single-arm study evaluating the addition of inotuzumab ozogamicin to a modified hyper-CVAD plus blinatumomab regimen in patients with B-cell acute lymphoblastic leukemia. Key Outcomes: The regimen achieved high remission and MRD-negative response rates with a low relapse rate, without an apparent increase in toxicity.
Open in Who Shared Issue with article?

Dr DeAngelo on Key Questions to Address in Acute Lymphoblastic Leukemia Management

|
By Alexander Pearson, Tycel Jovelle Phillips, Daniel DeAngelo
| OncLive
Daniel J. DeAngelo, MD, PhD, physician and chief of the Division of Leukemia at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School, discussed the evolving treatment strategies in acute lymphoblastic leukemia (ALL) management, particularly for patients with Philadelphia chromosome (Ph)–positive disease, which were discussed during the 2026 Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.
Open in Who Shared Issue with article?

Risk stratification of patients with TP53-mutated myeloproliferative neoplasms - Leukemia

|
By Benjamin Rolles, Nathan Fergusson, Jan Philipp Bewersdorf, Julia M Keating, Cecelia Perkins, Matthew Schwede, James England, Marlise R. Luskin, Daniel DeAngelo, Shai Shimony, Mifra Faiz, Addison C. Hillerbrand, Chulwoo Kim, Lachelle D. Weeks, Lauren Waldman, Mohammed Wazir, Joan How, Anna E. Marneth, Yiwen Liu, Martin J. Aryee, Raajit Rampal, Harrison K. Tsai, Jason Gotlib, Vikas Gupta, Maximilian Stahl, Ann Mullally
| Nature
Abstract While TP53 mutations in myeloproliferative neoplasms (MPN) are associated with an increased risk of leukemic transformation, not all patients carrying a TP53 mutation progress. To better risk-stratify MPN patients with TP53 mutations, we analyzed data from 1540 patients treated at four specialized cancer centers. Among them, 1429 had wildtype TP53 and 111 had mutations in the TP53 gene.
Open in Who Shared Issue with article?
See all 1,176 licensed articles (1,178 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Daniel

Contact Daniel, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified